|
In January 2007, BRM signed a contract with Michigan
State University (MSU)
to provide research services toward developing a drug
treatment for Diabetic Retinopathy. As part of the research
collaboration BRM is now positioned to evaluate the
MSU therapy as a possible treatment for diabetic renal
failure.
The University of California at San Francisco received
a seven year contract totaling $220 Million. The goal
of the funding is to perform clinical trials via the
Immune Tolerance Network (ITN) (www.immunetolerance.org).
ITN and BRM have entered into a contract with University
of California at San Francisco to perform preclinical
studies in autoimmunity including; Type 1 diabetes,
Multiple Sclerosis and Rheumatoid Arthritis.
PR
Newswire (USA)
January 11, 2007
PRNewswire-FirstCall
-- Neuralstem, Inc. (OTC Bulletin Board:
NRLS), headquartered here, announced today the execution
of an exclusive license agreement to Biomedical
Research Models, Inc. for the development of
Neuralstem compounds to treat certain cognitive and
neurological impacts of diabetes.
The agreement includes annual license fees until product
commercialization; milestone payments upon the completion
of agreed-upon clinical goals, which could total approximately
$38 million for each licensed product that is approved
by the FDA; as well as royalties on ensuing products.
The license covers a library of Neuralstem patent-pending
compounds, discovered using Neuralstem's patented human
neural stem cells. The company said that the compounds,
when orally administered, have been shown in adult mice
to recruit and stimulate the body's own stem cells to
form new neurons in the brain, and may be useful in
healing and protecting injured brain areas.
"What we have is a true platform technology,"
said Richard Garr, Neuralstem President and Chief Executive
Officer. "Neuralstem's ability to grow regionally
specific, physiologically relevant human nerve cells
in large quantities, in vitro (in dishes) provides a
unique tool for discovering drugs to treat neurological
and psychiatric diseases. It gives the company a way
to leverage our cells' unique properties in both our
cell therapy and drug development programs. Our licensee,
Biomedical Research Models, Inc., is
focused on developing novel drug therapies for the treatment
of diabetes, and will provide an excellent partner to
move the results of our drug discovery program forward
in this area."
Neuralstem recently received a $500,000 grant from the
NIH to study the possible effectiveness of its compounds
to treat depression. "The creation of Neuralstem's
unique drug discovery platform (patent-pending) was
funded by an award from the U.S. Department of Defense
several years ago," Garr added. "Neuralstem
retains the rights to these compounds for all indications
other than diabetes."
Biomedical
Research Models Inc. signed a five year contract with
the National Institutes of Diabetes Digestive and Kidney
Diseases (NIDDK) totaling $4,889,031.
The
objectives of this contract are to assist NIDDK in development
of potential new therapies for the prevention of Type
1 diabetes. The contract was competitively awarded after
BRM responded to RFP-NIDDK-05-05 entiltled: Preclinical
Studies of Efficacy in Animal Models of Type 1 diabetes.
Working closely with the government's T-1 RAID project
officer, BRM scientific staff along with consultants
and collaborators at the Pioneer Valley Life Science
Initiative will begin assessing novel therapies on behalf
of the government for entry into Trial-Net.
The
creation of this National Research Center to be based
in Worcester and Springfield, MA is part of the Congressionally
established Diabetes Research Working Groups Strategic
plan to Cure Diabetes in the 21st Century.
BRM
competed nationally for two T-1 RAID contracts. It was
selected as the semifinalist in January for both contracts.
The first contract was awarded in May to the University
of California at San Diego. UCSD is ranked #13 nationally
for USPHS-NIH funding. BRM a company that is ranked
in the top 25% of the 3,181 institutions that received
USPHS funding in 2004 out-competed another Top 25 research
institution based in California for this contract.
BRM's data on Environmental Pertubation
funded via SBIR grants will be featured in a plenary
session at the ADA's 66th Scientific Session scheduled
to convene inWashington, D.C. June 9th to the 13th.
The
symposia is titled "Nature vs. Nurture in Type
I Diabetes". This is a follow on to last
year's BRM abstract entitled "Maternal Immunization
Protects Weanling LEW.1WR1 Rats from Virus-Induced Diabetes",
which was selected for oral presentation at the ADA's
65th session held in San Diego, California.
AAALAC:
BRM
has been notified by the AAALAC International, Association
for Assessment and Accreditation of Laboratory Animal
Care that it is approved for FULL ACCREDITATION at all
of our 4 facilities and programs for Laboratory Animal
Care.
Worcester
Telegram & Gazette (MA) April 4, 2006.
Biomedical
Research Models, Inc. has received a one year
Small Business Innovation Research grant of $295,807
from the National Institute of Allergy and Infectious
Disease for work on a vaccine against herpes simplex
virus type 2, the company reported. The government health
institute is also recommending that BRM receive an additional
$287,298 next year for a second year of work on the
vaccine. BRM is a privately held life science company.
HSV-2 is the virus most often responsible for genital
herpes. BRM’s DNA vaccine and a follow-up booster
immunization are designed to raise an immune response
against disease-causing agents. The company plans to
test the vaccine first in mice.
BRM has been notified by the (NIDDK)
to be in the competitive range for two contracts entitled
"Preclinical Study of Efficacy in Animal Models
of Type 1 Diabetes" and "Preclinical Study
of Efficacy I Animal Models of Diabetic Complications".
NIDDK
has developed the T1D Rapid Access to Intervention Development
(RAID) program. Under the aegis of this program, resources
will be provided to investigators to bridge the gap
between discovery and clinical testing. A major component
of this program is in vivo efficacy testing.
To
support in vivo testing, an animal testing center that
can provide reliable, standardized, cost-effective studies
is required. Under our proposal, BRM would serve as
a primary resource for performing preclinical studies
in mice and rats to test new therapeutics for the prevention
and/or treatment of type 1 diabetes and it’s complications.
8/31/03 - The Republican,
Marcia Blomberg
Wednesday will mark the first day of work in a new,
state-of-the-art laboratory built by a private biomedical
company in Springfield's North End.
Official opening of Biomedical Research Model's lab,
built and equipped at an estimated cost of $1.2 million
to $1.4 million, marks a stride forward in the Pioneer
Valley Life Sciences Initiative's campaign to build
a biotechnology industry in the region.
3/2/03 - summarized from an article
in the Worcester Telegram and Gazette and 1/19/03 in
the Springfield Republican newsletter.
Being the first commercial
tenant in the brand-new Biomedical Research Institute
in Springfield’s North End, a new state of the
art 10,000 square foot home for research and development
efforts. Facility mirrors existing research lab at 10
New Bond Street in Worcester.
Expanding contract research operations, including Oral
Vaccine Technologies of Las Vegas (OVT), and working
on research funding of up to 2.25 million dollars in
federal grants from the National Institutes of Health.
~ MORE ~
|
Biomedical
Research Models has received a fundable priority score
of 155 for a phase 1 SBIR grant totaling $590,536, entitled
“A mucosal vaccine for HSV-2”.
The
project will be funded for a 2 year period of performance
beginning 3/1/06. The principal investigator on the
grant will be Rebecca S. Tirabassi, Ph.D. Research Director
and expert on human cytomegalovirus.
Biomedical
Research Models has been awarded a phase 1 SBIR grant
totaling $1,000,000, entitled
“Neurogenic
compounds for treating diabetic complications”.
The project is funded for
a 2 year period of performance which began 9/30/04 and
ends 8/31/06. The principal investigator on the grant
is Rebecca S. Tirabassi, Ph.D. Research Director and
expert on human cytomegalovirus.
Biomedical
Research Models has been awarded a phase 1 SBIR grant
totaling $393,589, entitled “In-stent
Stenosis model in type 2 diabetic rats”. The
project is to develop and validate a novel in-stent
stenosis animal model system to accelerate advances
in vascular disease therapeutics and device testing.
Funding is for a 2 year period of performance which
began 6/01/04 and ends 5/31/06. The principal investigator
on the grant is Tiangen Wu, M.D. Research Director.
Biomedical
Research Models has been awarded a phase 1 STTR grant
totaling $223,141, entitled
“Engineering Myoblasts for Transplantation”.
The
1.5 year project ran from July 1, 2004 – December
31, 2005. The principal investigator on the grant, Edward
H. Kislauskis, Ph.D., is the Vice President and co-founder
of BRM, Inc.
Biomedical
Research Models has been awarded a phase 1 SBIR grant
totaling $319,762, entitled
“New model for virus induced autoimmunity”.
The objective of the program
is to study the process of viral induction of autoimmune
diabetes. Funding is for a 1.5 year period of performance
which began 701/04 and ends 12/31/05. The principal
investigator on the grant is Dennis L. Guberski, M.S.,
President and founder of BRM.
Biomedical
Research Models Inc has been awarded a Phase 1 SBIR
grant totaling $342.704 to characterize the BBZDR rat
new model of Type 2 Diabetes. The project is
funded for a two-year period of performance, which began
on June 1, 2001. The Principal Investigator on the grant
is Dennis L. Guberski, the president and founder of
BRM Inc.
Biomedical
Research Models Inc has been awarded a Phase 1 SBIR
grant totaling $123,148 to develop an antibody directed
at Notch-1 receptors on stem cells. The project
is funded for a six-month period of performance, which
began on September 14, 2000. The Principal Investigator
on the grant is Edward H. Kislauskis Ph.D. the Vice
president and co-founder of BRM Inc. |
2007